CDMOs offering Process Development with Biologics (Monoclonal Antibodies)
51 published
51 published CDMOs match Process Development and Biologics (Monoclonal Antibodies).
Locations in this set include United States, China, Germany, India, Japan, and United Kingdom.
Capabilities that show up most often in this set: CMC Analytical Development, Recombinant Protein Manufacturing, Monoclonal Antibody (mAb) Manufacturing, Formulation Development, and Technology Transfer.
Matching companies
Samsung BiologicsLeading CDMO offering end-to-end biologics development and manufacturing from cell line development through aseptic fill-finish, with capabilities in drug substance, drug product, ADC, and mRNA services.
Scinai Immunotherapeutics Ltd.Boutique biologics CDMO providing analytical method development, process development, and cGMP manufacturing for biotech clients from early research through Phase 3, backed by over 20 years of experience and state-of-the-art facilities.
Sussex Research Laboratories Inc.Global leader in carbohydrate and glycan synthesis, offering custom synthesis, CRO, and CDMO services for drug discovery and development. Specializes in GalNAc targeting ligands, glycopeptides, and glycoconjugates with over 25 years of expertise.
Symbiosis Pharmaceutical ServicesUK-based fill-finish CDMO offering rapid access to GMP aseptic manufacturing for clinical and commercial injectable drug products across mAbs, ATMPs, ADCs, RNA, peptides, vaccines, and small molecules.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Vetter PharmaIndependent CDMO specialist in aseptic fill-finish, drug product development, analytical services, and combination product assembly with 76 years of experience and 7,300+ employees globally.
Wheeler BioOklahoma-based CDMO specializing in antibody-based therapeutics from cell line development through cGMP manufacturing. Offers ModularCMC platform with phase-appropriate work packages and high-touch project management.
WuXi BiologicsGlobal biologic CDMO offering end-to-end solutions from discovery to commercialization.
WuXi VaccinesGlobal CDMO specializing in end-to-end vaccine and prophylactic antibody development and manufacturing across mammalian, viral, and microbial platforms with GMP-certified facilities and over 550 million doses delivered.
WuXi XDCWuXi XDC is a leading CRDMO offering integrated discovery, development, and cGMP manufacturing services for antibody drug conjugates (ADCs) and bioconjugates, with proximately located facilities that reduce development timelines and costs.
Yapan BioYapan Bio provides integrated process development, characterization, and GMP manufacturing for vaccines, monoclonal antibodies, gene therapy, and viral vector-based biologics, with capabilities up to 1000L bioreactor scale and BSL-2+ containment.
Markdown mirror: /explore/process-development/biologics-monoclonal-antibodies.md